175 related articles for article (PubMed ID: 12843001)
1. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W; Mesters R; Tinnefeld H; Loges S; Staib P; Duhrsen U; Flasshove M; Ottmann OG; Jung W; Cavalli F; Kuse R; Thomalla J; Serve H; O'Farrell AM; Jacobs M; Brega NM; Scigalla P; Hossfeld DK; Berdel WE
Blood; 2003 Oct; 102(8):2763-7. PubMed ID: 12843001
[TBL] [Abstract][Full Text] [Related]
2. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.
Loges S; Tinnefeld H; Metzner A; Jücker M; Butzal M; Bruweleit M; Fischer U; Draab E; Schuch G; O'-Farrel AM; Hossfeld DK; Bokemeyer C; Fiedler W
Leuk Lymphoma; 2006 Dec; 47(12):2601-9. PubMed ID: 17169805
[TBL] [Abstract][Full Text] [Related]
4. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
5. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Giles FJ; Stopeck AT; Silverman LR; Lancet JE; Cooper MA; Hannah AL; Cherrington JM; O'Farrell AM; Yuen HA; Louie SG; Hong W; Cortes JE; Verstovsek S; Albitar M; O'Brien SM; Kantarjian HM; Karp JE
Blood; 2003 Aug; 102(3):795-801. PubMed ID: 12649163
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Zangari M; Anaissie E; Stopeck A; Morimoto A; Tan N; Lancet J; Cooper M; Hannah A; Garcia-Manero G; Faderl S; Kantarjian H; Cherrington J; Albitar M; Giles FJ
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):88-95. PubMed ID: 14734456
[TBL] [Abstract][Full Text] [Related]
7. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Smolich BD; Yuen HA; West KA; Giles FJ; Albitar M; Cherrington JM
Blood; 2001 Mar; 97(5):1413-21. PubMed ID: 11222388
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Giles FJ; Cooper MA; Silverman L; Karp JE; Lancet JE; Zangari M; Shami PJ; Khan KD; Hannah AL; Cherrington JM; Thomas DA; Garcia-Manero G; Albitar M; Kantarjian HM; Stopeck AT
Cancer; 2003 Apr; 97(8):1920-8. PubMed ID: 12673719
[TBL] [Abstract][Full Text] [Related]
9. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.
Mesters RM; Padró T; Bieker R; Steins M; Kreuter M; Göner M; Kelsey S; Scigalla P; Fiedler W; Büchner T; Berdel WE
Blood; 2001 Jul; 98(1):241-3. PubMed ID: 11418488
[TBL] [Abstract][Full Text] [Related]
10. [Dynamic observation of vascular endothelial growth factor (VEGF)/VEGF-receptors expression in acute leukemia].
Wang C; Chen FY; Zhu JS; Xu YP; Han JY; Ouyang RR
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):845-8. PubMed ID: 15634546
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
12. Role of angiogenesis inhibitors in acute myeloid leukemia.
Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Fiedler W; Serve H; Döhner H; Schwittay M; Ottmann OG; O'Farrell AM; Bello CL; Allred R; Manning WC; Cherrington JM; Louie SG; Hong W; Brega NM; Massimini G; Scigalla P; Berdel WE; Hossfeld DK
Blood; 2005 Feb; 105(3):986-93. PubMed ID: 15459012
[TBL] [Abstract][Full Text] [Related]
14. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Karp JE; Gojo I; Pili R; Gocke CD; Greer J; Guo C; Qian D; Morris L; Tidwell M; Chen H; Zwiebel J
Clin Cancer Res; 2004 Jun; 10(11):3577-85. PubMed ID: 15173063
[TBL] [Abstract][Full Text] [Related]
15. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
16. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
17. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Kindler T; Breitenbuecher F; Marx A; Hess G; Gschaidmeier H; Gamm H; Kirkpatrick CJ; Huber C; Fischer T
Blood; 2003 Apr; 101(8):2960-2. PubMed ID: 12480706
[TBL] [Abstract][Full Text] [Related]
18. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
19. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
20. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Stadler WM; Cao D; Vogelzang NJ; Ryan CW; Hoving K; Wright R; Karrison T; Vokes EE
Clin Cancer Res; 2004 May; 10(10):3365-70. PubMed ID: 15161690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
